Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to $11.1 million.

  • Ligand Pharmaceuticals' Other Operating Expenses changed N/A to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.2 million, marking a year-over-year decrease of 2576.45%. This contributed to the annual value of $2.1 million for FY2023, which is N/A changed from last year.
  • Ligand Pharmaceuticals' Other Operating Expenses amounted to $11.1 million in Q3 2025.
  • Ligand Pharmaceuticals' Other Operating Expenses' 5-year high stood at $37.7 million during Q2 2024, with a 5-year trough of $2.1 million in Q3 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' median Other Operating Expenses value was $12.3 million (recorded in 2023), while the average stood at $14.8 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 26886.76% in 2024, then plummeted by 6695.97% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Other Operating Expenses (Quarter) stood at $3.8 million in 2021, then soared by 249.45% to $13.3 million in 2022, then crashed by 84.03% to $2.1 million in 2023, then surged by 1675.29% to $37.7 million in 2024, then crashed by 70.61% to $11.1 million in 2025.
  • Its Other Operating Expenses stands at $11.1 million for Q3 2025, versus $12.4 million for Q2 2025 and $12.7 million for Q1 2025.